Literature DB >> 34206598

Prediction of Treatment Outcome with Inflammatory Biomarkers after 2 Months of Therapy in Pulmonary Tuberculosis Patients: Preliminary Results.

Simona Stefanescu1, Relu Cocoș2,3, Adina Turcu-Stiolica4, Elena-Silvia Shelby5, Marius Matei6, Mihaela-Simona Subtirelu4, Andreea-Daniela Meca7, Elena Camelia Stanciulescu8, Stefana Oana Popescu8, Viorel Biciusca9, Catalina-Gabriela Pisoschi8.   

Abstract

Pro-inflammatory mediators play an important role in the pathogenesis of pulmonary tuberculosis. Consecutively, 26 pulmonary tuberculosis patients were enrolled in our study based on the exclusion criteria. We have used Spearman's correlation analysis, hierarchical clustering and regression modelling to evaluate the association of 11 biomarkers with culture status after antituberculosis treatment. The results of our study demonstrated that six inflammatory biomarkers of 11, C-reactive protein (CRP), white blood cells (WBC), neutrophils, interferon gamma inducible protein 10, C-reactive protein (CRP) to albumin ratio (CAR) and neutrophil to albumin ratio (NAR), were significantly associated with culture negativity. The predictive ability of a composite model of seven biomarkers was superior to that of any single biomarker based on area under the receiver operating characteristic curve (AUC) analysis, indicating an excellent prediction efficacy (AUC:0.892; 95% CI:0.732-1.0). We also found that the highest significant trends and lower levels of CRP and IP-10 were observed in the two-month treated tuberculosis (TB) patients. We believe that our study may be valuable in providing preliminary results for an additional strategy in monitoring and management of the clinical outcome of pulmonary tuberculosis. Using a panel of predictors added a superior value in predicting culture status after anti-TB therapy.

Entities:  

Keywords:  C-reactive protein; CAR; IP-10; LL-37; NAR; pulmonary tuberculosis; white blood cells

Year:  2021        PMID: 34206598     DOI: 10.3390/pathogens10070789

Source DB:  PubMed          Journal:  Pathogens        ISSN: 2076-0817


  76 in total

1.  Mean platelet volume: a useful marker of inflammatory bowel disease activity.

Authors:  A N Kapsoritakis; M I Koukourakis; A Sfiridaki; S P Potamianos; M G Kosmadaki; I E Koutroubakis; E A Kouroumalis
Journal:  Am J Gastroenterol       Date:  2001-03       Impact factor: 10.864

2.  The relationship between inflammatory marker levels and pulmonary tuberculosis severity.

Authors:  Ozlem Abakay; Abdurrahman Abakay; Hadice Selimoglu Sen; Abdullah C Tanrikulu
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

3.  Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.

Authors:  M Ruhwald; T Bodmer; C Maier; M Jepsen; M B Haaland; J Eugen-Olsen; P Ravn
Journal:  Eur Respir J       Date:  2008-08-06       Impact factor: 16.671

4.  IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy.

Authors:  Basirudeen Syed Ahamed Kabeer; Alamelu Raja; Balambal Raman; Satheesh Thangaraj; Marc Leportier; Giuseppe Ippolito; Enrico Girardi; Philippe Henri Lagrange; Delia Goletti
Journal:  BMC Infect Dis       Date:  2011-05-19       Impact factor: 3.090

5.  Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis.

Authors:  Yung-Che Chen; Chien-Hung Chin; Shih-Feng Liu; Chao-Chien Wu; Chia-Cheng Tsen; Yi-Hsi Wang; Tung-Ying Chao; Chien-Hao Lie; Chung-Jen Chen; Chin-Chou Wang; Meng-Chih Lin
Journal:  Dis Markers       Date:  2011       Impact factor: 3.434

6.  IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection.

Authors:  Kristian Tonby; Morten Ruhwald; Dag Kvale; Anne Ma Dyrhol-Riise
Journal:  Sci Rep       Date:  2015-03-18       Impact factor: 4.379

7.  Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis.

Authors:  Song Yee Kim; Jungho Kim; Deok Ryun Kim; Young Ae Kang; Sungyoung Bong; Jonghee Lee; Suyeon Kim; Nam Suk Lee; Bora Sim; Sang-Nae Cho; Young Sam Kim; Hyejon Lee
Journal:  BMC Infect Dis       Date:  2018-05-29       Impact factor: 3.090

8.  Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.

Authors:  G B Sigal; M R Segal; A Mathew; L Jarlsberg; M Wang; S Barbero; N Small; K Haynesworth; J L Davis; M Weiner; W C Whitworth; J Jacobs; J Schorey; D M Lewinsohn; P Nahid
Journal:  EBioMedicine       Date:  2017-10-24       Impact factor: 8.143

9.  Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV.

Authors:  Katherine Farr; Resmi Ravindran; Luke Strnad; Emily Chang; Lelia H Chaisson; Christina Yoon; William Worodria; Alfred Andama; Irene Ayakaka; Priscilla Bbosa Nalwanga; Patrick Byanyima; Nelson Kalema; Sylvia Kaswabuli; Winceslaus Katagira; Kyomugisha Denise Aman; Emmanuel Musisi; Nuwagaba Wallen Tumwine; Ingvar Sanyu; Robert Ssebunya; J Lucian Davis; Laurence Huang; Imran H Khan; Adithya Cattamanchi
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

10.  Serum globulin and albumin to globulin ratio as potential diagnostic biomarkers for periprosthetic joint infection: a retrospective review.

Authors:  Yongyu Ye; Weishen Chen; Minghui Gu; Guoyan Xian; Baiqi Pan; Linli Zheng; Ziji Zhang; Puyi Sheng
Journal:  J Orthop Surg Res       Date:  2020-10-07       Impact factor: 2.359

View more
  1 in total

1.  Screening performance of C-reactive protein for active pulmonary tuberculosis in HIV-positive patients: A systematic review with a meta-analysis.

Authors:  Andreea-Daniela Meca; Adina Turcu-Stiolica; Maria Bogdan; Mihaela-Simona Subtirelu; Relu Cocoș; Bogdan Silviu Ungureanu; Beatrice Mahler; Catalina-Gabriela Pisoschi
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.